Parathyroid Adenoma Detection With Rubidium-82 Imaging

ConditionsParathyroid Adenomas Hyperparathyroidism, Primary

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorMatthieu Pelletier-Galarneau, MD MSc

About this trial

Assess the uptake of rubidium-82 in parathyroid adenomas.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18y

Ability to undergo imaging logistics

Ability to provide informed consent

Biochemical evidence of primary hyperparathyroidism

Disqualifiers

Normocalcemic primary hyperparathyroidism

Breastfeeding or pregnancy

Claustrophobia or inability to undergo imaging logistics

Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study

Trial population

20 participants with a diagnosis of primary parathyroid adenoma who have previously undergone 18F-fluorocholine imaging will be recruited.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

PET/CT imaging with rubidium-82
Other intervention
PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

Uptake pattern of rubidium-82 in parathyroid adenomas

Rudibium-82 uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.

Time frame

3 months

Secondary outcomes

Comparison between the uptakes of rubidium-82 and 18F-fluorocholine in patients with parathyroid adenomas

Radioactive tracer uptake will be compared between Rudibium-82 and 18F-Fluorocholine. Uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.

Time frame

3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Matthieu Pelletier-Galarneau, MD MSc

Lead sponsor

Montreal Heart Institute

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: